229 related articles for article (PubMed ID: 35460973)
1. Oncolytic viruses and pancreatic cancer.
Hamidi-Sofiani V; Rakhshi R; Moradi N; Zeynali P; Nakhaie M; Behboudi E
Cancer Treat Res Commun; 2022; 31():100563. PubMed ID: 35460973
[TBL] [Abstract][Full Text] [Related]
2. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
3. A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues.
Yamamoto Y; Hiraoka N; Goto N; Rin Y; Miura K; Narumi K; Uchida H; Tagawa M; Aoki K
J Control Release; 2014 Oct; 192():284-93. PubMed ID: 25108153
[TBL] [Abstract][Full Text] [Related]
4. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.
Nistal-Villan E; Bunuales M; Poutou J; Gonzalez-Aparicio M; Bravo-Perez C; Quetglas JI; Carte B; Gonzalez-Aseguinolaza G; Prieto J; Larrea E; Hernandez-Alcoceba R
Mol Cancer; 2015 Dec; 14():210. PubMed ID: 26671477
[TBL] [Abstract][Full Text] [Related]
5. The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer.
Sato-Dahlman M; Yamamoto M
Curr Cancer Drug Targets; 2018; 18(2):153-161. PubMed ID: 28228084
[TBL] [Abstract][Full Text] [Related]
6. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer.
Nakao A; Kasuya H; Sahin TT; Nomura N; Kanzaki A; Misawa M; Shirota T; Yamada S; Fujii T; Sugimoto H; Shikano T; Nomoto S; Takeda S; Kodera Y; Nishiyama Y
Cancer Gene Ther; 2011 Mar; 18(3):167-75. PubMed ID: 21102422
[TBL] [Abstract][Full Text] [Related]
7. A genetic fiber modification to achieve matrix-metalloprotease-activated infectivity of oncolytic adenovirus.
José A; Rovira-Rigau M; Luna J; Giménez-Alejandre M; Vaquero E; García de la Torre B; Andreu D; Alemany R; Fillat C
J Control Release; 2014 Oct; 192():148-56. PubMed ID: 25037019
[TBL] [Abstract][Full Text] [Related]
8. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.
Buijs P; van Nieuwkoop S; Vaes V; Fouchier R; van Eijck C; van den Hoogen B
Viruses; 2015 Jun; 7(6):2980-98. PubMed ID: 26110582
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Virotherapy: An Advanced Microbial Approach for the Management of Cancer.
Rao MFS; Ahmed B; Qadir MI
Crit Rev Eukaryot Gene Expr; 2024; 34(1):1-13. PubMed ID: 37824388
[TBL] [Abstract][Full Text] [Related]
11. Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.
Chu QD; Sun G; Pope M; Luraguiz N; Curiel DT; Kim R; Li BD; Mathis JM
Surgery; 2012 Sep; 152(3):441-8. PubMed ID: 22853858
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic adenovirus as pancreatic cancer-targeted therapy: Where do we go from here?
Yoon AR; Hong J; Jung BK; Ahn HM; Zhang S; Yun CO
Cancer Lett; 2023 Nov; 579():216456. PubMed ID: 37940067
[TBL] [Abstract][Full Text] [Related]
13. Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer.
Kangasniemi L; Parviainen S; Pisto T; Koskinen M; Jokinen M; Kiviluoto T; Cerullo V; Jalonen H; Koski A; Kangasniemi A; Kanerva A; Pesonen S; Hemminki A
Int J Cancer; 2012 Jul; 131(1):253-63. PubMed ID: 21834073
[TBL] [Abstract][Full Text] [Related]
14. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of Therapeutic Potential of Oncolytic Virus with Homologous Tumor Cell Membranes for Pancreatic Cancer.
Chen W; Liu H; Chen Y; Gao M
IET Nanobiotechnol; 2024; 2024():9970665. PubMed ID: 38863971
[TBL] [Abstract][Full Text] [Related]
16. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
17. Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration.
Na Y; Nam JP; Hong J; Oh E; Shin HC; Kim HS; Kim SW; Yun CO
J Control Release; 2019 Jul; 305():75-88. PubMed ID: 31071373
[TBL] [Abstract][Full Text] [Related]
18. The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer.
Haller SD; Monaco ML; Essani K
Viruses; 2020 Nov; 12(11):. PubMed ID: 33213031
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic adenoviruses and the treatment of pancreatic cancer: a review of clinical trials.
Taylor IP; Lopez JA
J Cancer Res Clin Oncol; 2023 Aug; 149(10):8117-8129. PubMed ID: 37031291
[TBL] [Abstract][Full Text] [Related]
20. Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice.
Kurosaki H; Nakatake M; Sakamoto T; Kuwano N; Yamane M; Ishii K; Fujiwara Y; Nakamura T
Cells; 2021 Apr; 10(5):. PubMed ID: 33922406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
